TP53 and cancer: The incomplete penetrance, despite the presence of pathogenic variants of TP53 in LFS suggests: (i) the presence of additional genetic and/or epigenetic driver events that contribute to cancer risk in certain individuals; and (ii) resilience mechanisms that explain the absence of cancer in some TP53-variant carriers, possibly initiated through alternative variants in compensatory pathways (11).